Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection

Summary

The main purpose of this study is to evaluate the activity of low dose oral selinexor (KPT-330) and to evaluate the clinical recovery, the viral load, length of hospitalization and the rate of morbidity and mortality in participants with severe COVID-19 compared to placebo. The study had 2 arms and evaluated selinexor 20 mg + standard of care (SoC) and placebo + SoC. As the treatment for COVID-19 is rapidly evolving, the SoC varied over time and across regions of the world.

Timeline

Start

2020-04-17

Primary completion

2020-10-05

Completion

2020-10-05

Drugs

Indications